D. Parasrampuria

发表

PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate.

Darin D Dougherty, Joseph Biederman, D. Dougherty, 2006, The American journal of psychiatry.

Delicate Dance in Treating Hepatitis C Infections and Overcoming Resistance

D. Parasrampuria, 2017 .

Do Formulation Differences Alter Abuse Liability of Methylphenidate?: A Placebo-Controlled, Randomized, Double-Blind, Crossover Study in Recreational Drug Users

E. Sellers, R. Schuller, P. Ciccone, 2007, Journal of clinical psychopharmacology.

Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis

T. Marbury, D. Parasrampuria, Shuquan Chen, 2015, Thrombosis and Haemostasis.

The impact of a three-factor prothrombin complex concentrate on the anticoagulatory effects of the factor Xa inhibitor edoxaban.

D. Parasrampuria, Ling He, K. Brown, 2015, Thrombosis research.

Phase 1–2 safety, efficacy and pharmacokinetic study of decitabine in sequential administration with cytarabine in children with relapsed or refractory acute myeloid leukaemia

P. Kearns, D. Reinhardt, C. Zwaan, 2019, British journal of haematology.

Biliary elimination of bromsulphthalein, phenolphthalein, and doxorubicin released from microspheres following intravenous administration

A. Hickey, D. Parasrampuria, M. Kanke, 1993, Biopharmaceutics & drug disposition.

Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open‐label Phase II study

S. Iida, C. Touzeau, A. Chari, 2020, British journal of haematology.

Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer

C. Drake, E. Antonarakis, D. McNeel, 2019, Prostate Cancer and Prostatic Diseases.

Population Pharmacokinetic Analysis of Decitabine in Pediatric Patients With Acute Myeloid Leukemia

I. Poggesi, D. Parasrampuria, Liping Zhang, 2018, Journal of clinical pharmacology.

Inclusion of Placebos and Blinding for Ascending Dose First‐in‐Human Studies and Other Underpowered Phase 1 Studies has not been Justified and on Balance is Not Useful

L. Benet, D. Parasrampuria, Dolly A. Parasrampuria, 2015, Basic & clinical pharmacology & toxicology.

Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study

S. Iida, H. Nahi, Kihyun Kim, 2021, Annals of Hematology.

Exposure‐Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients

H. Nahi, C. Touzeau, Yu‐Nien Sun, 2020, Journal of clinical pharmacology.

Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial.

J. Laubach, S. Iida, H. Nahi, 2020, The Lancet. Haematology.

Comparison of efficacy from two different dosing regimens of bortezomib: an exposure–response analysis

M. Dimopoulos, J. San-Miguel, M. Mateos, 2020, British journal of haematology.

Comparison of a transdermal contraceptive patch with a newly sourced adhesive component versus EVRA patch: A double-blind, randomized, bioequivalence and adhesion study in healthy women.

J. Natarajan, D. Parasrampuria, J. Massarella, 2020, Contraception.

KRAS: Structure, function, and development of anticancer drugs

D. Parasrampuria, A. Yu, N. Haddish-Berhane, 2020 .

Scientific diligence for oncology drugs: a pharmacology, translational medicine and clinical perspective.

D. Parasrampuria, T. Puchalski, R. Bandekar, 2020, Drug discovery today.

A Human Lymphocyte Based Ex Vivo Assay to Study the Effect of Drugs on P-glycoprotein (p-Gp) Function1

L. Benet, D. Parasrampuria, M. Lantz, 2004, Pharmaceutical Research.

Single‐Dose Pharmacokinetics and Pharmacodynamics of RWJ 67657, a Specific p38 Mitogen‐Activated Protein Kinase Inhibitor: A First‐in‐Human Study

A. Chow, P. Boer, D. Parasrampuria, 2003, Journal of clinical pharmacology.

Assessment of Pharmacokinetics and Pharmacodynamic Effects Related to Abuse Potential of a Unique Oral Osmotic‐Controlled Extended‐Release Methylphenidate Formulation in Humans

E. Sellers, R. Schuller, P. Ciccone, 2007, Journal of clinical pharmacology.

Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa

D. Parasrampuria, K. Truitt, 2015, Clinical Pharmacokinetics.

Edoxaban drug–drug interactions with ketoconazole, erythromycin, and cyclosporine

D. Parasrampuria, K. Truitt, H. Zahir, 2016, British journal of clinical pharmacology.

Single-Dose Pharmacokinetics and Metabolism of the Oral Decongestant Phenylephrine HCl in Children and Adolescents

D. Parasrampuria, C. Gelotte, B. Zimmerman, 2022, Pulmonary Therapy.

Subcutaneous Daratumumab Plus Standard Treatment Regimens in Patients with Multiple Myeloma across Lines of Therapy: Pleiades Study Update

S. Iida, C. Touzeau, A. Chari, 2019, Blood.

Efficacy and safety of the randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients (pts) with relapsed or refractory multiple myeloma (RRMM): COLUMBA.

J. Laubach, S. Iida, H. Nahi, 2019, Journal of Clinical Oncology.

Why Drugs Fail in Late Stages of Development: Case Study Analyses from the Last Decade and Recommendations

L. Benet, Amarnath Sharma, D. Parasrampuria, 2018, The AAPS Journal.

Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients with Relapsed or Refractory Multiple Myeloma: Columba Update

J. Laubach, S. Iida, H. Nahi, 2019, Blood.

Evaluation of regional gastrointestinal absorption of edoxaban using the enterion capsule

I. Wilding, A. Connor, K. Ogata, 2015, Journal of clinical pharmacology.

Manufacture and In-Vitro Assessment of Bromsulphthalein and Phenolphthalein Loaded Polyester Microspheres

A. Hickey, D. Parasrampuria, M. Kanke, 1994 .

PERCUTANEOUS DELIVERY OF PROTEINS AND PEPTIDES USING IONTOPHORETIC TECHNIQUES

D. Parasrampuria, J. Parasrampuria, 1991, Journal of clinical pharmacy and therapeutics.

Subcutaneous (SC) Daratumumab (DARA) in Combination With Standard Multiple Myeloma (MM) Treatment Regimens: An Open-label, Multicenter Phase 2 Study (PLEIADES)

H. Goldschmidt, S. Iida, P. Moreau, 2019, Clinical Lymphoma Myeloma and Leukemia.

Effect of Calcineurin Inhibitor Therapy on P‐gp Expression and Function in Lymphocytes of Renal Transplant Patients: A Preliminary Evaluation

L. Benet, F. Vincenti, D. Parasrampuria, 2002, Journal of clinical pharmacology.

Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis

T. Marbury, D. Parasrampuria, Shuquan Chen, 2015, Thrombosis and Haemostasis.

Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer

C. Drake, E. Antonarakis, D. McNeel, 2021, Prostate Cancer and Prostatic Diseases.

Pharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etexilate in Healthy Subjects

D. Parasrampuria, K. Brown, J. Maa, 2015, Clinical Drug Investigation.